Phase III COMPASS study shows Xarelto (rivaroxaban)+ aspirin significantly reduced major CV events.- Janssen Research Development + Bayer HealthCare.

Results from the pivotal Phase III COMPASS study found that the Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin 100 mg once daily significantly reduced the risk of major cardiovascular (CV) events defined as CV death, heart attack or stroke by 24% in patients with stable coronary and/or peripheral artery disease (CAD/PAD) compared to aspirin alone. This finding was driven by a robust 42% reduction in any stroke and 22% reduction in CV death.

The risk of major bleeding was significantly higher in patients taking the Xarelto/aspirin regimen compared to aspirin alone, with no significant increase in fatal or intracranial bleeds. Findings from this global, randomized, superiority study were announced by Janssen Research Development, LLC, presented during a Hot Line session at the ESC Congress 2017 and simultaneously published in The New England Journal of Medicine.